BIOMAT Database Logo BIOMAT Database Logo

Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models. 2014

Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
School of Physiology and Pharmacology, University of Bristol, Medical Sciences Building, University Walk, Bristol BS8 1TD, UK.

Defective epithelial ion transport is the hallmark of the life-limiting genetic disease cystic fibrosis (CF). This abnormality is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), the ATP-binding cassette transporter that functions as a ligand-gated anion channel. Since the identification of the CFTR gene, almost 2000 disease-causing mutations associated with a spectrum of clinical phenotypes have been reported, but the majority remain poorly characterised. Studies of a small number of mutations including the most common, F508del-CFTR, have identified six general mechanisms of CFTR dysfunction. Here, we review selectively progress to understand how CF mutations disrupt CFTR processing, stability and function. We explore CFTR structure and function to explain the molecular mechanisms of CFTR dysfunction and highlight new knowledge of disease pathophysiology emerging from large animal models of CF. Understanding CFTR dysfunction is crucial to the development of transformational therapies for CF patients.

UI MeSH Term Description Entries
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D019005 Cystic Fibrosis Transmembrane Conductance Regulator A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8) CFTR Protein,Chloride channels, ATP-gated CFTR,Chloride channels, ATP gated CFTR,Protein, CFTR

Related Publications

Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
Cystic fibrosis: How do CFTR mutations cause cystic fibrosis?
December 1995, Current biology : CB,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
CFTR mutations and cystic fibrosis.
October 2013, Prescrire international,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
Understanding how cystic fibrosis mutations cause a loss of Cl- channel function.
July 1996, Molecular medicine today,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
May 2011, Current drug targets,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
CFTR mutations in Chilean cystic fibrosis patients.
September 1994, Human genetics,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
October 2003, The New England journal of medicine,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
Treatment of cystic fibrosis based on understanding CFTR.
January 1995, Society of General Physiologists series,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
Treatment of cystic fibrosis based on understanding CFTR.
January 1995, Journal of inherited metabolic disease,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
Novel CFTR mutations in black cystic fibrosis patients.
April 2004, Clinical genetics,
Yiting Wang, and Joe A Wrennall, and Zhiwei Cai, and Hongyu Li, and David N Sheppard
Distribution of CFTR gene mutations in cystic fibrosis patients from Estonia.
August 2000, Journal of medical genetics,
Copied contents to your clipboard!